SERENTIL® (MESORIDAZINE BESYLATE) HAS BEEN SHOWN TO PROLONG THE QTc INTERVAL IN A DOSE RELATED MANNER, AND DRUGS WITH THIS POTENTIAL, INCLUDING SERENTIL, HAVE BEEN ASSOCIATED WITH TORSADE DE POINTES-TYPE ARRHYTHMIAS AND SUDDEN DEATH. DUE TO ITS POTENTIAL FOR SIGNIFICANT, POSSIBLY LIFE-THREATENING, PROARRHYTHMIC EFFECTS, SERENTIL SHOULD BE RESERVED FOR USE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE TO ADEQUATE COURSES OF TREATMENT WITH OTHER ANTIPSYCHOTIC DRUGS, EITHER BECAUSE OF INSUFFICIENT EFFECTIVENESS OR THE INABILITY TO ACHIEVE AN EFFECTIVE DOSE DUE TO INTOLERABLE ADVERSE EFFECTS FROM THOSE DRUGS. (SEE WARNINGS, CONTRAINDICATIONS, AND INDICATIONS.)
SERENTIL® (mesoridazine besylate), the besylate salt of a metabolite of thioridazine, is a phenothiazine antipsychotic. Serentil is 10-[2(1-methyl-2-piperidyl)ethyl]-2-(methyl-sulfinyl)-phenothiazine [as the besylate].
Serentil® (mesoridazine besylate) is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life-threatening, proarrhythmic effects with Serentil treatment, Serentil should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with Serentil, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS).
However, the prescriber should be aware that Serentil has not been systematically evaluated in controlled trials in treatment of refractory schizophrenic patients and its efficacy in such patients is unknown.
Media Articles Related to Serentil (Mesoridazine)
Cognitive Therapy May Reduce Insomnia in Patients With Schizophrenia
Source: Medscape Medical News Headlines [2015.10.02]
Cognitive behavioral therapy (CBT) may reduce insomnia in patients with persistent delusions or hallucinations, a new study suggests.
Reuters Health Information
ERs Often 'Safety Net' Care for People With Schizophrenia: CDC
Source: MedicineNet Schizophrenia Specialty [2015.09.24]
Title: ERs Often 'Safety Net' Care for People With Schizophrenia: CDC
Category: Health News
Created: 9/23/2015 12:00:00 AM
Last Editorial Review: 9/24/2015 12:00:00 AM
Repairing the brain - Two genes unlock potential for treatment of schizophrenia
Source: Schizophrenia News From Medical News Today [2015.09.21]
Research led by scientists from Duke-NUS Graduate Medical School Singapore (Duke-NUS) has linked the abnormal behaviour of two genes (BDNF and DTNBP1) to the underlying cause of schizophrenia.
Vraylar Approved for Schizophrenia, Bipolar Disorder
Source: MedicineNet Bipolar Disorder Specialty [2015.09.21]
Title: Vraylar Approved for Schizophrenia, Bipolar Disorder
Category: Health News
Created: 9/18/2015 12:00:00 AM
Last Editorial Review: 9/21/2015 12:00:00 AM
FDA approves new drug to treat schizophrenia and bipolar disorder
Source: Bipolar News From Medical News Today [2015.09.18]
The U.S. Food and Drug Administration has approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults.
Published Studies Related to Serentil (Mesoridazine)
Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. [2007.11]
We compared the effects of single doses of thioridazine and mesoridazine on the heart rate-corrected QT (QTc) interval in healthy adult volunteers. QTc intervals and plasma concentrations of thioridazine, mesoridazine, and metabolites were measured after single oral doses of thioridazine hydrochloride 50 mg, mesoridazine besylate 50 mg, or placebo in a double-blind, crossover study...
Clinical Trials Related to Serentil (Mesoridazine)
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin [Recruiting]
Recent but limited short term studies have shown that Metformin can slow down weight gain in
obese children and in children with psychotropic-induced weight gain, two distinct pediatric
populations that are at risk for obesity related co-morbid conditions. The purpose of this
study is to conduct a long term prospective pilot cohort study to investigate the use of
Metformin to prevent or decrease weight gain in two cohorts of children: 1) children with
psychotropic induced weight gain on Metformin and 2) children with BMI above the 95th
percentile on Metformin. Both study populations will be enrolled in a lifestyle weight
Page last updated: 2015-10-02